Tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) can induce apoptosis
in a wide variety of cancer cells, both in vitro and in vivo, importantly without killing any …

The discovery that the tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) can
induce apoptosis of cancer cells without causing toxicity in mice has led to the in-depth study …

Acute kidney injury (AKI) exhibits high morbidity and mortality. Kidney injury molecule-1
(KIM1) is dramatically upregulated in renal tubules upon injury, and acts as a biomarker for …

Receptor clustering on the cell membrane is critical in the signaling of many
immunoreceptors, and this mechanism has previously been attributed to the extracellular …

Disruption of protein folding in the endoplasmic reticulum (ER) activates the unfolded protein
response (UPR)—a signaling network that ultimately determines cell fate. Initially, UPR …

The nanoscale spatial organization of transmembrane tumor necrosis factor (TNF) receptors
has been implicated in the regulation of cellular fate. Accordingly, molecular tools that can …

Radiotherapy and chemotherapy are two famous modalities in tumor‐targeted therapy that
lead to systemic and local toxicities for normal tissues. Moreover, several studies have …

Death receptor agonist therapies have exhibited limited clinical benefit to date.
Investigations into why Apo2L/TRAIL and AMG 655 preclinical data were not predictive of …

Tumor necrosis-factor related apoptosis-inducing ligand, also known as TRAIL or APO2L
(Apo-2 ligand), is a cytokine of the TNF superfamily acknowledged for its ability to trigger …

Members of the tumor necrosis factor receptor superfamily (TNFRSF) are important
therapeutic targets that can be activated to induce death of cancer cells or stimulate …